Latest News
Immune cells undergo non-inherited genetic changes that are associated with higher Alzheimer’s risk.
Brightfocus supports a groundbreaking $28M investment by the Canadian Institutes of Health Research to bolster early-career health researchers from historically under-recognized groups.
BrightFocus President and CEO Stacy Pagos Haller spoke with WebMD about the latest breakthroughs in macular degeneration research.
A new study asks the question: what if we could reverse the damage caused by Alzheimer’s disease-related proteins like tau? Learn more.
Newly released research portfolios highlight the 276 biomedical research projects funded by BrightFocus Foundation across 16 countries to defeat Alzheimer’s disease, macular degeneration, and glaucoma.
The anti-amyloid therapy will go off the market later this year.
January is Glaucoma Awareness Month, and BrightFocus Foundation is pleased to announce the 2024 schedule of Glaucoma Chats, free, accessible and interactive audio podcast conversations with leading glaucoma specialists and eye care professionals.
The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg). iDose TR is a first-of-its kind treatment that is designed to provide up to three years of 24/7, continuous drug therapy directly inside the eye, helping people with glaucoma take control over the elevated eye pressure associated with this vision disease.
BrightFocus Foundation, in partnership with three other global vision loss advocacy organizations, has declared Dec. 5 as World Geographic Atrophy Day.
In a new BrightFocus-funded study, researchers found an association between alterations in circadian rest-activity rhythms and risk of frailty incidence in older adults.
